ProShare Advisors LLC trimmed its holdings in shares of IVERIC bio, Inc. (NASDAQ:ISEE – Get Rating) by 33.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,192 shares of the company’s stock after selling 11,354 shares during the quarter. ProShare Advisors LLC’s holdings in IVERIC bio were worth $213,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ISEE. Captrust Financial Advisors grew its stake in IVERIC bio by 14,900.0% during the 1st quarter. Captrust Financial Advisors now owns 1,500 shares of the company’s stock worth $25,000 after buying an additional 1,490 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in IVERIC bio by 36.9% during the 1st quarter. Nisa Investment Advisors LLC now owns 3,230 shares of the company’s stock worth $54,000 after buying an additional 870 shares during the last quarter. Adviser Investments LLC purchased a new position in IVERIC bio during the 2nd quarter worth $103,000. Parametrica Management Ltd purchased a new position in IVERIC bio during the 2nd quarter worth $104,000. Finally, HighTower Advisors LLC purchased a new position in IVERIC bio during the 1st quarter worth $214,000.
Analysts Set New Price Targets
Several research analysts recently weighed in on the company. Guggenheim boosted their target price on IVERIC bio from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, September 7th. B. Riley raised IVERIC bio from a “sell” rating to a “neutral” rating in a research report on Monday, October 17th. Stifel Nicolaus lifted their price target on IVERIC bio from $28.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, September 8th. Robert W. Baird lifted their price target on IVERIC bio from $27.00 to $34.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 7th. Finally, StockNews.com raised IVERIC bio to a “sell” rating in a research report on Wednesday, October 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.00.
IVERIC bio Stock Up 0.1 %
IVERIC bio Profile
IVERIC bio, Inc, a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
- Get a free copy of the StockNews.com research report on IVERIC bio (ISEE)
- Nomad Foods: A Defensive Stock on the Move
- The Market Is Suddenly All Ears on Warner Music Group
- Uber Stock Surge On The Back Of Profitabilty
- Online Lender SoFi Jumps 14% On Better-Than-Expected Q3 Results
- Strong Q3 Driving Growth At S&P 500 Component Citizens Financial
Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.